A phase I combination dose-escalation study of eribulin mesylate and gemcitabine in patients with advanced solid tumours: a study of the Princess Margaret Consortium

Stephanie Lheureux,Amit M. Oza,Scott A. Laurie,R.A. Halford,Derek J. Jonker,Eric X. Chen,Deborah Keller,V Bourade,Lisa Wang,L.A. Doyle,Lillian L. Siu,R. Goel

A phase I combination dose-escalation study of eribulin mesylate and gemcitabine in patients with advanced solid tumours: a study of the Princess Margaret Consortium

2015

Stephanie Lheureux
Amit M. Oza
Scott A. Laurie
R.A. Halford
Derek J. Jonker
Eric X. Chen
Deborah Keller
V Bourade
Lisa Wang
L.A. Doyle
Lillian L. Siu
R. Goel

A phase I combination dose-escalation study of eribulin mesylate and gemcitabine in patients with advanced solid tumours: a study of the Princess Margaret Consortium

Keywords:

Immunology
Pathology
Eribulin Mesylate
Deoxycytidine
Gemcitabine
Lung cancer
Medicine
Response Evaluation Criteria in Solid Tumors
in patient
anti cancer drugs
dose escalation

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations